National Institute of Respiratory Diseases, Mexico

🇲🇽Mexico

Country: 🇲🇽Mexico

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)

Phase 3

Completed

Conditions: Severe Acute Respiratory Syndrome
COVID-19

Interventions: Drug: Placebo oral tablet
Drug: Hydroxychloroquine

First Posted Date: 2020-03-23

Last Posted Date: 2022-02-01

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 289

Registration Number: NCT04318015

Locations: 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico

Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)

Phase 3

Completed

Conditions: COVID-19
Severe Acute Respiratory Syndrome

Interventions: Drug: Placebo oral tablet
Drug: Hydroxychloroquine

First Posted Date: 2020-03-20

Last Posted Date: 2022-02-01

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 320

Registration Number: NCT04315896

Locations: 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico

Anti-inflammatory Effect of Nocturnal NIPPV on Acute Asthma

Not Applicable

Completed

Conditions: Asthma Acute

Interventions: Device: NIPPV
Device: CPAP

First Posted Date: 2017-05-16

Last Posted Date: 2019-08-28

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 20

Registration Number: NCT03154762

Locations: 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, Ciudad de México, Mexico

Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy

Not Applicable

Conditions: Steinert Disease
Myotonic Dystrophy 1

Interventions: Device: Non Invasive Ventilation.

First Posted Date: 2016-08-26

Last Posted Date: 2018-07-11

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 27

Registration Number: NCT02880735

Locations: 🇲🇽
National Institute Of Respiratory Diseases, Mexico, Mexico

Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)

Phase 4

Completed

Conditions: COPD

Interventions: Drug: indacaterol
Drug: Tiotropium

First Posted Date: 2015-06-16

Last Posted Date: 2015-10-16

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 40

Registration Number: NCT02473237

Locations: 🇲🇽
Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas", Mexico, City, Mexico

Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis

Phase 4

Conditions: Asthma
Asthmatic Crisis

Interventions: Drug: Extra fine Formoterol/Beclomethasone

First Posted Date: 2015-01-26

Last Posted Date: 2015-04-03

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 120

Registration Number: NCT02345993

Locations: 🇲🇽
National Institute of Respiratory Diseases, Mexico, Distrito Federal, Mexico

Exacerbation Prevention GOLD IV COPD With Non Invasive Mechanical Ventilation

Phase 4

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Device: BiPAP Pro 2, Phillips Respironics
Device: CPAP sham

First Posted Date: 2011-11-29

Last Posted Date: 2015-05-25

Lead Sponsor: National Institute of Respiratory Diseases, Mexico

Target Recruit Count: 20

Registration Number: NCT01481727

Locations: 🇲🇽
National Institute of Respiratory Diseases, Mexico City, Mexico

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy